



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/698,870	10/27/2000	Redford B. Williams JR.	5405.239	5914

20792 7590 07/26/2002

MYERS BIGEL SIBLEY & SAJOVEC
PO BOX 37428
RALEIGH, NC 27627

EXAMINER

SOUAYA, JEHANNE E

ART UNIT PAPER NUMBER

1634

DATE MAILED: 07/26/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/698,870

Applicant(s)

WILLIAMS, REDFORD B.

Examiner

Jehanne Souaya

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1634

DETAILED ACTION

Election/Restriction

1. The election/restriction requirement made in the previous office action, mailed 3/27/2002 has been withdrawn. Consequently, an action on the merits of claims 1-16 follows.

Priority

2. Applicant's claim for benefit of priority from application 60/162,390 is acknowledged. However, the claims have not been awarded the benefit of the filing date of the '390 application because the claimed subject matter is not present in the '390 application. The '390 application is directed to an association between diseases, such as cardiovascular diseases, and presence of the short allele of the serotonin transporter gene promoter. Further, the '390 application does not demonstrate an association between cardiovascular diseases, or any diseases, in response to stress and the long allele of the serotonin transporter gene promoter.

Claim Rejections - 35 USC § 112

Indefinite

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1634

4. Claims 1-16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 6 lack sufficient antecedent basis for the phrase "said subject" as it is unclear whether this refers to the "human subject" previously recited in the claims. This rejection can be overcome by reciting instead --said human subject--.

Enablement

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 1-16 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. There are many factors to be considered when determining whether there is sufficient evidence to support determination that a disclosure does not satisfy the enablement requirements and whether any necessary experimentation is undue (See *In re Wands*, 858 F. 2d 731, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)). These factors include, but are not limited to:

Quantity of Experimentation Necessary
Amount of Direction and Guidance
Presence and Absence of Working Examples

Art Unit: 1634

Nature of the Invention

Level of predictability and unpredictability in the art

Nature of the Invention

The claims are broadly drawn to screening human subjects for increased risk of disease in response to stress by determining the presence of at least one serotonin transporter gene promoter long allele in a subject wherein the presence of at least one long allele serotonin transporter gene promoter genotype indicates that the subject is at increased risk of any disease in response to stress. The claims are further drawn to embodiments wherein the disease is cardiovascular disease, cancer, autoimmune disease, delayed wound healing, and gastrointestinal disease. The claims are also broadly drawn to screening human subjects for increased risk of infectious disease wherein the presence of at least one long allele serotonin transporter gene promoter genotype indicates that a subject is at increased risk of infectious disease, wherein the infectious disease can be as claimed in any of claims 7-15. Further, claim 1 does not recite any specific disease or type of stress, therefore the claim (and claims dependent therefrom with regard to the latter) broadly encompass any disease in response to any kind of stress. The specification further broadly defines “stress” as any physical or psychological stimulus that induces a physical stress response (see p. 4, lines 29-32).

Presence and Absence of Working Examples

The specification has no working examples, whatsoever, of any studies or methods that associated the presence of any of the claimed diseases in human subjects with at least one long

Art Unit: 1634

allele of the serotonin transporter gene promoter, either in combination or not with response to stress.

Amount of Direction and Guidance

The specification teaches analyzing human subjects, not including those with medical or psychiatric disorders or current medication use, for 5HIAA levels (primary serotonin metabolite) in response to tryptophan depletion and response to the antagonist pindolol. The specification further analyzes differences in biological responses to tryptophan depletion or infusion, such as heart rate, mean arterial pressure, epinephrine and norepinephrine levels, cortisol levels, and prolactin levels in subjects with either short or long serotonin transporter gene promoter polymorphisms. The specification, however, does not provide any examples of an association between the presence of any of the claimed diseases and subjects with the long allele serotonin transporter gene polymorphism. Thus, while the study provided in the specification illustrates that subjects with different serotonin transporter gene promoter alleles have different biological responses to tryptophan infusion or depletion, the specification does not analyze the association between the presence of any of the claimed diseases and the long allele of the serotonin transporter gene promoter in subjects either in the presence or absence of a response to stress. It would essentially be a trial and error process to determine whether subjects with the long allele of the serotonin transporter gene promoter polymorphisms were in fact at an increased risk for developing any of either the broadly claimed category of diseases (ie: cardiovascular diseases,

Art Unit: 1634

autoimmune diseases, infectious diseases, gastrointestinal diseases) or specific infectious diseases (ie: influenza, tuberculosis).

Level of predictability and unpredictability in the art

The art teaches that associations between the serotonin transport gene promoter alleles and different diseases is unpredictable. For example, Persico et al (American Journal of Medical Genetics, vol. 96, pp 123-127, 2000) teach that family based studies provide conflicting evidence of linkage or association between either the short or the long allele of the serotonin transporter gene promoter in subjects with autistic disorder (see abstract) despite the fact that elevated serotonin blood levels have been consistently found in approximately 30-50% of autistic patients (see p. 123, col. 1, 2nd para). Further, Kunugi et al (American Journal of Medical Genetics, vol. 96, pp 307-309, 2000, abstract only) teach that while two independent research groups consistently reported a significant association between the serotonin transporter gene promoter short allele and late onset sporadic Alzheimer's disease, Kunugi et al could not find an association between such an allele and either early or late onset Alzheimer's disease in a Japanese population. Further, the post filing date art does not teach of any associations between any of the claimed diseases and either of the serotonin transporter gene promoter alleles, in combination or not with response to stress. Thus the art not only fails to support the efficacy of the invention, but in fact, supports the unpredictability of associating serotonin transport gene promoter alleles and different diseases, even diseases which were previously found to be associated with one of the alleles.

Art Unit: 1634

Quantity of Experimentation necessary

The quantity of experimentation in this area is extremely large since the claims are broadly drawn to broad categories of diseases and any type of stress and the specification does not support the scope of the broadly claimed invention. Case law has established that “(t)o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without ‘undue experimentation.’” *In re Wright* 990 F.2d 1557, 1561. *In re Fisher*, F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) it was determined that “(t)he scope of the claims must bear a reasonable correlation to the scope of enablement provided by the specification to persons of ordinary skill in the art”. The amount of guidance needed to enable the invention is related to the amount of knowledge in the art as well as the unpredictability in the art. Furthermore, the Court in *Genetech Inc. V Novo Nordisk* 42 USPQ2d 1001 held that “(I)t is the specification, not the knowledge of one skilled in the art that must supply the novel aspects of the invention in order to constitute adequate enablement”.

To be able to practice the invention as broadly as it is claimed, that is to determine that a subject is at an increased risk for any disease in response to stress, at an increased risk for any of the claimed diseases in response to stress, or at an increased risk for any infectious disease or any of the claimed infectious diseases, merely based on the presence of at least one long allele of the serotonin transporter gene promoter, the skilled artisan would have to perform a large number of studies, that included a sufficient number of subjects suffering from different types of cardiovascular diseases, cancers, autoimmune diseases, gastrointestinal diseases, infectious

Art Unit: 1634

diseases, as well as a sufficient number of control subjects, in the presence of and absence of different types of stress, to determine if in fact, a subject could be determined to be at an increased risk for developing any type of disease, or the diseases claimed, based on that subject having at least one long allele of the serotonin transporter gene promoter polymorphism.

Given the lack of guidance from the specification and the unpredictability taught in the art, such a study would be replete with trial and error analysis, the results of which are unpredictable. There is no teaching in either the specification or the art that the long allele of the serotonin transporter gene promoter is associated with *any* cardiovascular disease, such as hypertension, hypotension, or aneurysms, or gastrointestinal diseases, infectious diseases, delayed wound healing, cancers, or autoimmune diseases. These diseases each represent a large category of different disorders and diseases, wherein in many cases, each disease in the large category are involved with different biological mechanisms and genes and are associated with different risk factors and response to therapies. The specification merely provides an invitation for further experimentation and the claims are broadly drawn to methods that basically represent a research project, such research project requiring extensive trial and error analysis and which results are unknown and unpredictable, as illustrated by the state of the art at the time of filing.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1634

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 1 and 2 are rejected under 35 U.S.C. 102(b) as being anticipated by Arinami et al., (Thrombosis Haemostasis, vol. 81, pp 853-856, June 1999).

The claims are drawn to a method of screening human subjects for increased risk of disease, wherein the disease is cardiovascular disease (claim 2), by determining the presence of at least one serotonin transporter long allele in a subject wherein the presence of at least one long allele serotonin transporter gene promoter genotype indicates that said subject is at increased risk of disease in response to stress. Arinami teaches of analyzing patients with coronary artery disease for a serotonin transporter gene promoter polymorphism (see abstract, pp 853-854). Arinami teaches that the L allele (the long allele) was observed more frequently in patients with coronary heart disease ($p < 0.03$) and that this association was stronger ($p < 0.003$) in patients that also smoked. Since the claims do not make clear what type of stress is encompassed by the claims, the term "stress" has been broadly interpreted to include stress due to smoking. The teachings of Arinami teach a study which analyzed (screened) for an association between coronary heart disease (cardiovascular disease) and the long allele of the serotonin transport gene promoter in patients who smoked, and therefore, the teachings of Arinami anticipate the instantly claimed invention.

Art Unit: 1634

Conclusion

9. No claims are allowable.
10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Souaya whose telephone number is (703)308-6565. The examiner can normally be reached Monday-Friday from 9:00 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jehanne Souaya
Jehanne Souaya
Patent examiner
Art Unit 1634
July 25, 2002